Journal · Updated 2026-08-11
Ro Review 2026: The Insurance Concierge That Earns Its Category — and the Cash Price That Doesn't
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Ro completed its pivot to a brand-plus-concierge model: FDA-approved medication with an insurance operation that runs the benefits verification, assembles the prior authorization, and fights the appeal — the workflow that turns "covered in theory" into a twenty-five-dollar copay in practice, and the reason Ro holds our computed best-with-insurance category. The other half of the ledger: for coverage that fails, Ro's cash all-ins run roughly four forty-eight to five ninety-eight at maintenance — reseller pricing the manufacturers' own channels beat at every rung. The review is the split, held honestly: category winner on one axis, non-contender on the other.
Why the concierge is worth a category
The insurance path fails in practice at three human steps — the benefits call nobody makes, the PA documentation nobody assembles, the appeal nobody files — and Ro's operation exists to do exactly those, at scale, with the follow-through an individual rarely sustains. For the covered-but-blocked patient (the plan lists Zepbound, the PA feels impossible), that service routinely converts a five-hundred-dollar cash problem into a twenty-five-dollar solved one — value no cash-tier program on this site can touch, and the precise reason our computed categories give Ro a crown NexLife doesn't contest. The diligence is simply sequencing: confirm at intake that coverage runs first, that the cash tier is a fallback rather than a funnel, and what the concierge costs if the answer is a covered copay.
The cash half, and verdict
When coverage fails, Ro's roughly four forty-eight-to-five ninety-eight all-ins face the same arithmetic as every brand reseller: LillyDirect and NovoCare sell the identical products for two ninety-nine-to-four forty-nine and one forty-nine-to-three forty-nine with no membership, and the compounded flat tier runs a third the price for the unapproved cousin. So the verdict is a routing rule, not a rating: insured or plausibly insurable → start at Ro and let the concierge work; confirmed cash-pay → start at the manufacturers' counters and don't look back. The buyers who get this wrong in both directions — cash payers absorbing reseller premiums, covered patients never filing the PA — are this market's two most expensive mistakes, and Ro is simultaneously the fix for one and an instance of the other.
Questions people ask
What does Ro actually do for GLP-1 coverage?
The three steps patients abandon: verifies your benefits, assembles and submits the prior authorization with the documentation plans require, and runs the appeal on denial — the workflow that converts listed-but-blocked coverage into a $25 copay. It's why Ro wins our computed best-with-insurance category.
How much is Ro without insurance?
Roughly $448–$598/month all-in at maintenance for brand medication — reseller pricing that LillyDirect ($299–$449) and NovoCare ($149–$349) beat at every rung with no membership. Cash payers should start at the manufacturers' channels.
Should I use Ro or go direct to LillyDirect/NovoCare?
Sequence by coverage: insured or plausibly insurable → Ro, so the concierge can chase the $25–$50 copay; confirmed cash-pay → direct channels, where the same products cost less. Ask Ro at intake to run coverage first and to state what the service costs if a covered copay lands.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.